Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone

Nephrology Dialysis Transplantation

Volumn 20, Issue 9, 2005, Pages 1904-1911

  Iwasaki Ishizuka, Yoshiko ^a   Yamato, Hideyuki ^b   Nii Kono, Tomoko ^c   Kurokawa, Kiyoshi ^d   Fukagawa, Masafumi ^c  

^a OITA UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Japan)

^b KUREHA CORPORATION   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adynamic bone disease; Animal model; Bone histomorphometry; Renal failure; Skeletal resistance to parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; LEVOTHYROXINE; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE STRUCTURE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CELL FUNCTION; CELL SURFACE; CHRONIC KIDNEY FAILURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; HORMONE RESISTANCE; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; PATHOGENESIS; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM;

ACTINS; ALKALINE PHOSPHATASE; ANIMALS; BASE SEQUENCE; BONE AND BONES; DISEASE MODELS, ANIMAL; DNA PRIMERS; DRUG RESISTANCE; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; OSTEOBLASTS; PARATHYROID HORMONE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, PARATHYROID HORMONE, TYPE 1; THYROXINE;

EID: 24044508606     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh876     Document Type: Article

References (21)

1. Malluche HH, Ritz E, Lange HP et al. Bone histology in incipient and advanced renal failure. Kidney Int 1976; 9: 355-362
2. Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 1993; 43: 436-442
3. Hercz G, Pei Y, Greenwood C et al. Aplastic osteodystrophy without aluminum: The role of 'suppressed' parathyroid function. Kidney Int 1993; 44: 860-866
4. Couttenye MM, D' Haese PC, Verschoren WJ, Behets GJ, Schrooten I, De Broe ME. Low bone turnover in patients with renal failure. Kidney Int 1999; 73: S70-S76
5. Atsumi K, Kushida K, Yamazaki K et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999; 33: 287-293
6. Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994; 46: 855-861
7. Hutchison AJ, Whitehouse RW, Freemont AJ et al. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 1994; 14: 19-29
8. Goodman WG. Vascular calcification in end-stage renal disease. J Nephrol 2002; [Suppl 6]: S82-S85
9. Massry SG, Coburn JW, Lee DB et al. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann Intern Med 1973; 78: 357-364
10. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1989; 2: 595-610
11. Tallon S, Berdud I, Hernandez A et al. Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic rats. Kidney Int 1996; 49: 1441-1446
12. Berudud I, Martin-Malo A, Almaden Y et al. The PTH-calcium relationship during a range of infused PTH doses in the parathyroidectomized rat. Calcified Tissue Int 1998; 62: 457-461
13. Szabo A, Freesmeyer MG, Abendroth K et al. Physiological doses of calcium regulatory hormones do not normalize bone cells in uremic rats. Eur J Clin Invest 1999; 29: 529-535
14. Tanaka S, Sakai A, Tanaka M et al. Skeletal unloading alleviates the anabolic of intermittent PTH (1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells. J Bone Miner Res 2004; 19: 1813-1820
15. Buxton EC, Yao W, Lane NE. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). J Clin Endocrinol Metab 2004; 89: 3332-3336
16. Kazama JJ, Shigematsu T, Yano K et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-532
17. Ureña P, Mannstadt M, Hruby M et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor downregulation in uremic rats. Kidney Int 1995; 47: 1797-1805
18. Picton ML, Moore PR, Mawer EB et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000; 58: 1440-1449
19. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761
20. Lund RJ, Davies MR, Brown AJ et al. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 2004; 15: 359-369
21. Disthabanchong S, Hassan H, McConkey CL et al. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. Kidney Int 2004; 65: 897-903